Andy Boswell - Distinguished Scientist Development, Preclinical and Translational Pharmacokinetics, Development Sciences (joint appointment with Biomedical Imaging), Development Sciences

Andy Boswell

Distinguished Scientist Development, Preclinical and Translational Pharmacokinetics, Development Sciences (joint appointment with Biomedical Imaging), Development Sciences

Postdoc Mentor
"I am driven by the opportunity to apply a multidisciplinary approach to drug development in an effort to improve patients’ lives."
17
Years at Genentech
48
Publications at Genentech
8
Awards & Honors

Since joining Genentech in 2007, I have been responsible for understanding the absorption, metabolism, distribution and excretion of many of our large molecule therapeutics to help ensure that we achieve adequate drug exposure in the appropriate tissue compartments. In the Investigative Pharmacokinetics group, we apply a multidisciplinary approach to characterize the biodistribution of antibodies, including radiochemical, biochemical and molecular imaging techniques. Our group provides support across all therapeutic areas, including neuroscience and ophthalmology for which there are unique challenges in drug delivery and development. In my lab, we strive to provide guidance in designing and selecting the best molecule as well as the appropriate dose and regimen to achieve the pharmacologic exposure needed for efficacy.

Post Doctoral Mentor

My research vision is focused at the interface of chemistry and biology, with particular interest in using radiochemical probes to aid in the design, delivery and development of large molecule therapeutics. Our lab is uniquely poised to combine quantitative tissue-level radiometric drug measurements with cell-level fluorescence microscopic evaluation of receptor occupancy and tissue penetration. The ability to tackle scientific questions that arise in drug development presents a unique opportunity for a successful postdoctoral research project.

Featured Publication

Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-Length Antibodies.

Mol Cancer Ther. 2020 19(4): 1052-1058.

Nazarova L, Rafidi H, Mandikian D, Ferl GZ, Koerber JT, Davies CW, Ulufatu S, Ho J, Lau J, Yu SF, Ernst J, Sadowsky J and Boswell CA.